Baird analyst Brian Skorney lowered the firm’s price target on Eiger BioPharmaceuticals to $3 from $29 and keeps an Outperform rating on the shares. The analyst said although the experimental arms in it D-LIVR trial technically met statistical signficance on the primary endpoint, the results fell well short of what he see as viable for commercialization.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EIGR: